[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital of Navarra\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100645313","analysis-of-the-role-of-the-microbiota-in-diverticular-disease-100645313",false,"NCT07681505","Analysis of the Role of the Microbiota in Diverticular Disease","Analysis of the Role of the Microbiota in Diverticular Disease.","Inclusion Criteria:\n\n* Age 18 or older.\n* Signing of the informed consent form.\n* Assignment to one of the study groups mentioned above.\n\nExclusion Criteria:\n\n* An episode of acute diverticulitis located in the right colon or transverse colon.\n* Antibiotic treatment within the six weeks prior to the episode (except for antibiotics started in the emergency department or within 24 hours prior to sample collection).\n* Mechanical bowel preparation within the three weeks prior to sample collection.\n* Diagnosis of colorectal cancer.\n* Diagnosis of inflammatory bowel disease.\n* Failure to sign the informed consent form.","ALL","18 Years",{"count":19,"type":20},285,"ESTIMATED","24 Months","OBSERVATIONAL","A single-center, prospective observational cohort study conducted at the University Hospital of Navarra. The primary objective is to expand knowledge of diverticular disease and its pathological variants, as well as the influence of the microbiota in our environment, both clinically and molecularly; to describe the clinical and pathological characteristics of patients with diverticulosis and acute diverticulitis; to analyze any differences in the microbiota; and to identify the risk factors and groups associated with diverticular disease in order to establish the best strategies for prevention and treatment.",[25,26,27],"Diverticular Disease of Colon","Acute Diverticulitis","Gut Microbiota","NOT_YET_RECRUITING","2026-06-26",{"date":31,"type":32},"2026-07-02","ACTUAL",{"date":34,"type":20},"2027-06-01",{"date":36,"type":20},"2032-01-01",{"name":38,"class":39},"Hospital of Navarra","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":62,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":40},"100584672","application-of-indocyanine-green-tracer-in-d2-lymphadenectomy-of-locally-advanced-gastric-cancer-100584672","NCT06892392","Application of Indocyanine Green Tracer in D2 Lymphadenectomy of Locally Advanced Gastric Cancer","Aplicación Del ICG En La Linfadenectomía D2 Laparoscópica Del Cáncer Gástrico Localmente Avanzado: Ensayo Clínico Aleatorizado Multicéntrico.","Gastri-ICG","Inclusion Criteria:\n\n* T2-T4a, N+, M0 on preoperative study\n* PS 0-1\n* ASA I-III\n* Laparoscopic surgery\n\nExclusion Criteria:\n\n* \\- Previous gastric abdominal surgery\n* DSE\n* Cognitive impairment\n* Allergic to iodine\n* Synchronous neoplasm\n* Stroke in the last 6 months\n* Angina or AMI in the last 6 months\n* Plastic lymphitis\n* Open surgery","85 Years",{"count":51,"type":20},102,"INTERVENTIONAL",[54],"NA","Gastric cancer is a frequent neoplasm in the world, presenting more than one million new cases and around 768,000 deaths in the data registered in 2020. Among the therapeutic options for gastric cancer, surgery is an essential pillar for its treatment. Gastric cancer surgery consists of gastric resection with negative margins and radical lymphadenectomy in patients without distant metastases. It has been demonstrated over the years that radical lymphadenectomy in gastric cancer allows for adequate staging and improved long-term survival.\n\nIn order to perform a correct staging using the TNM system, it is necessary to resect at least 15 lymph nodes in the radical lymphadenectomy. For radical lymphadenectomy staging, the Japanese Gastric Cancer Association defined and subdivided nodal stations. Three types of lymphadenectomy are described according to oncologic gastric resections (D1, D1+ and D2), with D2 lymphadenectomy being the standard of treatment for locally advanced gastric tumors. Performing an insufficient or inadequate lymphadenectomy has been shown to negatively impact survival after gastrectomy in such a cohort.\n\nThe development of technology based on fluorescence guided by indocyanine green could improve the technique and results of D2 lymphadenectomy in patients with gastric cancer. There is evidence that the application of ICG in D2 lymphadenectomy increases the number of resected nodes, however, studies of higher scientific quality (randomized clinical trials) are needed. Furthermore, most studies in this field have focused on Eastern countries (Japan, Korea and China), where the percentage of early tumors and chemotherapy treatment is different from Western centers.\n\nTherefore, we propose a multicenter randomized clinical trial aimed at evaluating whether the application of ICG-guided fluorescence-based technology in D2 lymphadenectomy of locally advanced gastric cancer increases the number of resected nodes, improves the oncologic quality of the lymphadenectomy, and thus may increase overall survival and disease-free survival at 2 and 5 years postoperatively.",[57,58,59,60,61],"GASTRIC CANCER","Indocyanine Green (ICG)","Lymph Node Excision","Lymphadenectomy","Laparoscopic Gastrectomy",[63,64,65],"Multicenter randomized 1:1 clinical trial","indocyanine green","Laparoscopic gastrectomy with D2 lymphadenectomy","2025-03-18",{"date":68,"type":32},"2025-03-24",{"date":70,"type":20},"2026-03-01",{"date":72,"type":20},"2032-12",{"name":38,"class":39},""]